Updated from 10 a.m. ET to include CEO comments and afternoon share prices
NEW YORK ( TheStreet) -- E I Du Pont De Nemours (DD - Get Report) said Tuesday it is exploring "strategic alternatives" for its Performance Chemicals unit, as the industrial giant tries to focus on higher margin food and energy businesses.
While DuPont's possible sale of the under-performing chemicals business is likely to be viewed positively by shareholders, most notably the company's new investor Nelson Peltz of Trian Fund Management, it may put the over 200-year old company's future as a component of the Dow Jones Industrial Average at risk.
Already DuPont is one of the smallest Dow Industrials components, with a market cap just over $52 billion as of Monday's close. A spin-off or sale of the Performance Chemicals business, which generated about 20% of the company's overall revenue last year and a similar share of profits, could drop the company below the size of Hewlett Packard (HPQ), the next smallest Dow member.In that sense, DuPont's potential corporate restructuring could mirror a similar dismantling at Kraft (KFT), another large Trian Fund Management investment. Peltz, often an activist shareholder, was one of the investors driving Kraft to break itself into Mondelez (MDLZ - Get Report) and Kraft Foods (KFT). After Kraft's spin-off of Kraft Foods in 2012, the company was dropped from the Dow. It is no surprise then that Peltz has become an investor in DuPont just as the company begins to consider ways to rationalize its chemicals, foods and energy businesses. "DuPont's review of strategic alternatives for its Performance Chemical segment may include a full or partial separation of each of these businesses from the company through a spin-off, sale or other transaction," the company said in a Tuesday press release. The unit includes DuPont's Titanium Technologies and Chemicals & Fluoroproducts businesses which generated revenue of $7.2 billion in 2012. DuPont said it could look at sales of each business individually. In a telephone interview, DuPont spokesperson Michael Hanretta said it was too early to speculate beyond the company's announcement of its strategic review. DuPont CEO Ellen Kullman wouldn't speak about how a sale or spin-off would impact the company's 45 cent quarterly dividend. "It's, as we said, a strong business for the company. But it's cyclical, it's volatile, and it's low growth," Kullman said of DuPont's performance chemicals business on the Tuesday morning conference call with investors. Even if DuPont does sell or spin its performance chemicals business in full, there is no guarantee the company's ultimate strategy will be to get smaller. In 2012, the company sold its well-known car paint unit to private equity firm Carlyle Group (CG) for $4.9 billion, in a deal that came at about the same time the company was integrating a $5.8 billion acquisition of Danish food and biofuel enzyme maker Danisco. With $7 billion in cash on DuPont's balance sheet and further possible financial flexibility in a performance chemicals spin-off, the company could be laying the foundation for further transformation. A spin-off could allow DuPont to push harder into foods and energy businesses and encroach on markets dominated by Dow Chemicals (DOW), Monsanto (MON - Get Report) and FMC Corp. (FMC). Spin-offs and a strategic re-positioning of DuPont towards higher margin businesses through M&A activity may also be the company's easiest path to rising stock market performance in coming years. "Given the recent move in DuPont's share price, on top of its impressive year-to-date performance, it is not obvious to us that there is a clear path to meaningful incremental shareholder value creation absent further actions across the balance of the portfolio and/or material use of the balance sheet," Vincent Andrews, a Morgan Stanley analyst, wrote in a Monday client note.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts